After going through the storm of the epidemic, the pharmaceutical group has undergone a major transformation in its operations with the launch of niche products, the entry of royalties, and the overseas market. In 2023, it will usher in a golden age and enter an era of high profitability.It is estimated by the legal person that Baorui, Lamex, Shengtai, Sinochem, Shengda, Dongyang, Baoling, Xufu, Nanguang and other companies have the opportunity to start from half of the share capital, and the overall biotechnology industry profit will set a new high。
In addition, the recording of royalties in drug certificates and authorization cases will be the best performance in history, and the biotechnology and pharmaceutical industry in 2023 will enter a new generation.
The United Investment and Research Department pointed out that the advantages and changes of Taiwan’s biotechnology in 2023 include: (1) The long-term profit trend is good, the theme is diverse, and the geopolitical risk is much lower than that of the manufacturing industry, which will help compete for funds. (2) The market will seek the new mainstream after Polaris-KY and Sinopharm. (3) From a single-track market that is excessively concentrated on the dream group to a double-track benign rotation between the high-profit (high-growth) group and the dream group in 2023.
From a fundamental point of view, the profit king of the pharmaceutical industry in 2023 will be Borui and Lamex. The group stocks will be the big winners with Shengda, Shengtai, and Shengzhan. The most uniform performance is API group.
Lamex benefited from the launch of anti-blood cancer drugs in the United States in September 2022, driving the EPS in the first three quarters to hit a new annual high of 10.96 yuan. Since 2023 is the annual contribution, according to the order volume of distributors, it will be released in 3 to 4 times. The profit of the goods has jumped, and the initial estimate of the legal person in 2023 has a chance to look at 18-20 yuan.
Pharmaceutical profit Wang Baorui, after officially merged into Ancheng Pharmaceuticals in September 2022, the legal person is optimistic about the annual after-tax profit of 20 yuan per share; in 2023, new orders from CDMO, new customers, and Dexilant generic drug for the treatment of gastroesophageal reflux Sales growth, operating profit is expected to maintain a good level.
Nam Kwong’s anti-inflammatory drug “Ming De Sheng” injection has been purchased by the mainland for three years at a time, with an initial estimate of annual shipments of 10 million doses. Currently, it has entered a 24-hour overtime state and will have a strong explosive force starting in 2023.
Due to the expiry of the global patent of Biophos for the new kidney drug, Baoling no longer needs to pay the original inventor 50% of the sales profit. In addition, there is a chance to obtain the mainland drug certificate in 2023 and 2024.
further reading
Taiwan’s server factory looks prosperous and welcomes a good winter with 4 eye-catching gears
Bank of Japan sees rising inflation valuation as prelude to rate hike
14 concept fund cards for the Spring Festival, this shipping stock is eye-catching